Radiation therapy in urinary cancer: state of the art and perspective

Troiano, Michele; Corsa, Pietro; Raguso, Arcangela; Cossa, Stefano; Piombino, Michele; Guglielmi, Giuseppe; Parisi, Salvatore

doi:10.1007/s11547-008-0347-5

Cited by 4 publications

(3 citation statements)

References 72 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mean D2cc for urethra was 76 (±16) Gy after vaginal brachytherapy [2]. Data on cancers of the urethra are few and inconclusive [4]. Surgery, till date, is the curative treatment of carcinoma in urethra.…”

Section: Discussionmentioning

confidence: 99%

Intraluminal urethral brachytherapy for recurrence of transitional cell carcinoma of urinary bladder in urethral stump

Chakrabarti¹,

Ghorai²,

Ray³

et al. 2013

jcb

View full text Add to dashboard Cite

We report a unique case of successfully performed intraluminal brachytherapy for low volume urethral mucosal recurrence of transitional cell carcinoma urinary bladder, initially treated by transurethral resection of bladder tumor, followed by radical cystectomy. Since the patient was unwilling to undergo any other operational interventions, intraluminal brachytherapy of urethra was attempted. Fluroscopy guided intraluminal HDR brachytherapy using Lumencath® catheter under local anesthesia, and remote afterloading system (Nucletron, an Elekta company, Elekta AB, Stockholm, Sweden) was performed. A fraction dose of 7 Gy in seven weekly fractions was prescribed at 0.5 cm from the single applicator. The result was promising in terms of local control and symptomatic relief. Therefore, intraluminal brachytherapy in low volume superficial local disease in urethra may play a potential role, and should be applied when repeated surgery is not feasible due to technical or medical reasons.

show abstract

Section: Discussionmentioning

confidence: 99%

Intraluminal urethral brachytherapy for recurrence of transitional cell carcinoma of urinary bladder in urethral stump

Chakrabarti¹,

Ghorai²,

Ray³

et al. 2013

jcb

View full text Add to dashboard Cite

show abstract

“…Overall survival rates are approximately 50% for anterior tumors and 6% for entire tumors ( 1 ). Due to the rarity of these neoplasms, more data on radiotherapy is needed ( 6 ). Indications are that disease specific survival may be improved with a multimodality approach that uses surgery and adjuvant concurrent chemoradiotherapy ( 4 , 6 ).…”

Section: Discussionmentioning

confidence: 99%

Adenocarcinoma of the female urethra: Clear-cell variant

Caplan¹,

Hartman²,

Rooker³

2011

Radiology Case Reports

View full text Add to dashboard Cite

Primary urethral carcinoma is a rare malignancy with an annual age-adjusted incidence rate of 1.5 per million in females in the U.S. The three main histologic subtypes include transitional-cell carcinoma, squamous-cell carcinoma, and adenocarcinoma. Of these, adenocarcinoma is the least common. Female urethral carcinomas are aggressive neoplasms with a generally poor prognosis. We report a case of the clear-cell variant of adenocarcinoma.

show abstract

“…With recent advances in the use of more targeted radiotherapies such as intensity-modulated RT, which has been shown in some studies to significantly reduce the volume of normal tissues affected while treating a variety of abdominopelvic tumors, neoadjuvant radiotherapy may resurface as a potential investigative option for patients with bladder cancer. 41,42…”

Section: Radiation Therapymentioning

confidence: 99%